  |
 |
Program:
Current Issues in
Pharmaceutical Price Regulation
in Canada
A forum to share information, ideas and views on current issues in drug price regulation in Canada!
| Program (PDF) |
Presentations
Brady, Bruce, Canadian Coordinating Office for Health Technology
Assessment
Assessing
the value of new drugs: Where is Canada heading? || biography
Chiles, Vernon, Vice Chair of the Board, Green Shield Canada
Green
Shield Canada: Where quality is more than a claim || biography
Decter, Michael B., Chairman, Canadian Institute for Health Information
Health Care
Expenditure: Current Trends || biography
Elgie, Dr. Robert G.,
Chairperson of the Patented Medicine Prices Review Board, Canada
english
How the Patented Medicine Prices Review Board Contributes to Controlling Drug Prices in Canada || biography
français
La contribution du Conseil d’examen du prix des médicaments brevetés à la réglementation des prix des médicaments au Canada || biographie
Jacobzone, Stephane, OECD Health Project
Pharmaceuticals
regulation across OECD Countries
Maximising value for money to improve health system performance
|| biography
Kanavos, Panos,
Lecturer in International Health Policy, LSE Health and Social Care, UK
Approaches
to Pharmaceutical Regulation in Europe and the USA || biography
Keon, Jim,
President, Canadian Drug Manufacturers Association (CDMA)
Current
Issues in Pharmaceutical Price Regulation in Canada
"Is it Time to Rethink Canada's Pharmaceutical Patent Policy"
|| biography
Laupacis, Dr. Andreas,
President and Chief Executive Officer,
Institute for Clinical Evaluative Sciences (ICES)
Institute
for Clinical Evaluative Sciences: Economic Evaluation || biography
Lievonen, J. Mark,
President, Aventis Pasteur Limited
The
Future of Pharmacotherapy || biography
MacLeod, Stuart,
Professor, Clinical Epidemiology and Biostatistics,
Pediatrics and Medicine, McMaster University
The
National Prescription Drug Utilization Formation System (NPDUIS):
How can it be used to promote optimal drug therapy? || biography
McCool, Terry,
Vice President, Corporate Affairs, Eli Lilly Canada Inc.
Assessing
the Value of New Drugs: Where is Canada Heading The Industry Perspective
|| biography
Morgan, Steve,
Centre for Health Services and Policy Research, University of British
Columbia
The Future
of Pharmacotherapy in ten minutes or less || biography
Poston, Dr. Jeffrey,
Executive Director, Canadian Pharmacists Association
Comments
on a National Prescription Drug Utilization Information System
|| biography
Sansom, Professor Lloyd,
Chair, Pharmaceutical Benefits Advisory Committee, Australia
Assessing
the Value of New Drugs || biography
Shea, Barbara,
Executive Director, Drug Plan and Extended Benefits, Saskatchewan Health
NPDUIS
Provincial Perspective || biography
Shugart, Ian,
Assistant Deputy Minister, Health Policy and Communications, Health Canada
The
National Prescription Drug Utilization Information System: How can it
be used to promote optimal drug therapy and pharmaceuticals management?
|| biography
Tholl, William G.,
Secretary General and Chief Executive Officer
Canadian Medical Association
The Future
of Pharmacotherapy || biography